Drug intelligence / Profile preview

PSP NEURO SERUM

Development stage: Phase 3
Modality: Small Molecules
Administration: Topical

Overview

PSP NEURO SERUM is a topical formulation containing gonyautoxins, which are a type of neurotoxin. It is currently being investigated in a proof-of-concept clinical study for its effects on chemotherapy-induced peripheral neuropathy (CIPN). The drug aims to improve tactile sensitivity and overall neurological function in patients suffering from CIPN.

Other names: gonyautoxins

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on PSP NEURO SERUM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSP NEURO SERUM.

Explore the full profile